Nektar Therapeutics (NKTR) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last twelve months. There are currently 2 sell ratings and 3 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NKTR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NKTR, but not buy additional shares or sell existing shares.
View NKTR analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12-month target prices for Nektar Therapeutics' stock. Their NKTR share price forecasts range from $1.00 to $3.00. On average, they expect the company's share price to reach $2.40 in the next year. This suggests a possible upside of 292.2% from the stock's current price.
View analysts price targets for NKTR or view top-rated stocks among Wall Street analysts.

Nektar Therapeutics' stock was trading at $2.26 at the start of the year. Since then, NKTR shares have decreased by 72.9% and is now trading at $0.6119.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our NKTR earnings forecast.

Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.11. The biopharmaceutical company earned $22.02 million during the quarter, compared to the consensus estimate of $22.21 million. Nektar Therapeutics had a negative net margin of 467.00% and a negative trailing twelve-month return on equity of 84.36%. The company's revenue was down 11.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.79) earnings per share.

ETFs with the largest weight of Nektar Therapeutics (NASDAQ:NKTR) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Inspire Small/Mid Cap ETF (ISMD) and

46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (18.79%), State Street Corp (3.69%), Pictet Asset Management SA (1.97%), Geode Capital Management LLC (1.86%), Renaissance Technologies LLC (1.59%) and AQR Capital Management LLC (1.45%). Insiders that own company stock include Curet Myriam, Gil M Labrucherie, Gil M Labrucherie, Howard W Robin, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jillian B Thomsen, John Northcott, Jonathan Zalevsky, Karin Eastham, Mark Andrew Wilson, Myriam Curet, R Scott Greer and Robert Chess.
View institutional ownership trends.

Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NKTR stock can currently be purchased for approximately $0.61.

Nektar Therapeutics (NASDAQ:NKTR) has a market capitalization of $115.80 million and generates $92.06 million in revenue each year. The biopharmaceutical company earns $-368,200,000.00 in net income (profit) each year or ($2.21) on an earnings per share basis.

The company employs 740 workers across the globe.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The official website for the company is www.nektar.com. The biopharmaceutical company can be reached via phone at (415) 482-5300, via email at investors@nektar.com, or via fax at 415-339-5300.